Home > Oncology > ELCC 2022 > Early-Stage Non-Small Cell Lung Cancer > Consistent efficacy of osimertinib in Chinese and global population

Consistent efficacy of osimertinib in Chinese and global population

Presented By
Dr Jie Wang, Beijing Cancer Hospital, China
Presented by
Jie Wang Beijing Cancer Hospital, China
Conference
ELCC 2022
Trial
Phase 3, ADAURA
Doi
https://doi.org/10.55788/9cf01ffe
The efficacy and safety data of adjuvant osimertinib treatment in the Chinese subgroup of the phase 3 ADAURA trial are consistent with the results of the global population. Previously, the phase 3 ADAURA trial (NCT02511106) demonstrated a significant disease-free survival (DFS) benefit of adjuvant treatment with osimertinib versus placebo in patients with stage IB–IIIA, resected, EGFR-mutated non-small cell lung cancer (NSCLC) [1]. Because EGFR mutation is a common characteristic in Chinese lung cancer patients, a subgroup analysis of Chinese participants of ADAURA was performed. Dr Jie Wang (Beijing Cancer Hospital, China) presented the results [2]. Of 682 patients globally enrolled in ADAURA, 159 patients (68 patients with stage IB disease, 91 patients with stage II–IIIA disease) originated from 30 centres in China; 77 in the osimertinib...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on